Stockscreener 앱 받기
52.92
0.04%
0.02
시간 외 거래:
52.92
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
Neurocrine pairs $811M quarter with $2.9B Soleno deal for rare-disease drug - Stock Titan
Neurocrine Biosciences (NBIX) posts strong Q1 2026 results and plans $2.9B Soleno deal - Stock Titan
Big Q1 2026 jump as Neurocrine (NASDAQ: NBIX) inks $2.9B Soleno buy - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Neurocrine in the spotlight: Can growth justify Soleno bet? By Investing.com - Investing.com UK
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - ChartMill
DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of - GlobeNewswire
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
SLNO DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Soleno Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors - GlobeNewswire
Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - TMX Newsfile
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar - GlobeNewswire
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline - GlobeNewswire Inc.
SLNO DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Soleno Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
SLNO DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO - Scott Coop
Deadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - ChartMill
SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
Soleno Therapeutics (SLNO) price target decreased by 15.57% to 57.53 - MSN
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Eastern Progress
Soleno Therapeutics 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ACCESS Newswire
MSN Money - MSN
symbol__ Stock Quote Price and Forecast - CNN
Soleno Therapeutics 96 Hour Deadline Alert: Kahn Swick & Foti, LL - The National Law Review
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Soleno Therapeutics, ... - Caledonian Record
Soleno Therapeutics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - Business Wire
Soleno Therapeutics Executive Compensation, Corporate Governance, and Pay Practices 2025 - Minichart
Soleno Therapeutics (SLNO) Surges Nearly 60% In April Amid Neurocrine Acquisition Deal - Insider Monkey
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Pictet Asset Management Holding SA Has $28.90 Million Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - ChartMill
Neurocrine to acquire Soleno Therapeutics (SLNO) in $53-per-share cash deal - Stock Titan
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - MSN
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ChartMill
SLNO Shareholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - Morningstar
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT - GlobeNewswire
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting DCCR Safety Timeline: SueWallSt – Company AnnouncementFT.com - Financial Times
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud - GuruFocus
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Hav - GuruFocus
SOLENO DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - TMX Newsfile
[SC TO-T/A] SOLENO THERAPEUTICS INC Amended Third-Party Tender Offer | SLNO SEC FilingForm SC TO-T/A - Stock Titan
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
MSN - MSN
SHAREHOLDER ALERT Securities Class Action Filed Against Soleno Therapeutics, Inc. (SLNO) - TMX Newsfile
SOLENO DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sole - The National Law Review
Soleno Therapeutics (SLNO) Projected to Post Earnings on Wednesday - MarketBeat
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application - GlobeNewswire
SOLENO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Soleno Therapeutics, Inc. Investors ... - Caledonian Record
Soleno Therapeutics, Inc. Class Action ReminderRobbins LLP Encourages SLNO Investors to Contact the Firm for Information About Their Rights - ACCESS Newswire
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO - ChartMill
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Sees Large Drop in Short Interest - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
0.14%
0.48%
자본화:
|
볼륨(24시간):